ArticleFrontiers in oncology2025
Pegylated recombinant human granulocyte colony-stimulating factor enhances radiotherapy completion and safety in concurrent chemoradiotherapy for cervical cancer: a retrospective analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the impact of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on radiotherapy completion rates and safety in cervical cancer patients undergoing concurrent chemoradiotherapy. Methods: This retrospective study analyzed 60 cervical cancer patients treated at the researchers' hospital between October 2021 and October 2024. The patients were divided into two groups: the PEG-rhG-CSF group (n = 30), which received pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), and the non-PEG-rhG-CSF group (n = 30), which received recombinant human granulocyte colony-stimulating factor (rhG-CSF). Key outcomes, including radiotherapy completion time, hematological toxicity, and non-hematological adverse events, were compared between the two groups. Results: The results demonstrated that 83.33% of patients in the PEG-rhG-CSF group completed radiotherapy within 8 weeks, compared to 51.72% in the non-PEG-rhG-CSF group. The time to bone marrow suppression was significantly longer in the PEG-rhG-CSF group (4.93 ± 0.22 weeks) than in the non-PEG-rhG-CSF group (4.07 ± 0.22 weeks). Additionally, the lowest white blood cell (WBC) count in the PEG-rhG-CSF group was 2.46 ± 0.13 × 10 Conclusion: The study demonstrates that PEG-rhG-CSF has significantly improved radiotherapy completion rates and reduced the incidence of grade 3/4 leukopenia and neutropenia in cervical cancer patients undergoing concurrent chemoradiotherapy. Additionally, PEG-rhG-CSF has exhibited a favorable safety profile, with manageable adverse effects, making it a promising supportive treatment option in this setting. Synopsis: This study explores the application of PEG-rhG-CSF in concurrent chemoradiotherapy for cervical cancer. A retrospective analysis evaluates its effectiveness in helping patients' complete radiotherapy on time, reducing hematologic toxicity, and ensuring safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.